Peritoneal Cancer News

Peritoneal Cancer - Pipeline Review, H2 2017 - Markets Insider



Medgadget
 
Peritoneal Cancer - Pipeline Review, H2 2017 
Markets Insider
Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal ...
Peritoneal Cancer ? Pipeline Review, H2 2017- Understanding the Focus Areas of Leading Companies Medgadget (blog)

all 11 news articles » 


IBCN 2017: Outcomes - UroToday - UroToday



IBCN 2017: Outcomes - UroToday 
UroToday
IBCN 2017, bladder cancer, Laura S. Mertens, Stephen B. Williams, Neema Navai, Stephen B. Williams and Ashish M. Kamat.

and more » 


H2 2017 Peritoneal Cancer Industry Pipeline Review Size, Share ... - Medgadget (blog)



H2 2017 Peritoneal Cancer Industry Pipeline Review Size, Share ... 
Medgadget (blog)
Description: The Global Peritoneal Cancer report has been prepared keeping in mind the need of the customers for the latest information in the Peritoneal C.

and more » 


New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients - Surviving Mesothelioma



Surviving Mesothelioma
 
New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients 
Surviving Mesothelioma
The researchers conclude that, while it is ?feasible? to deliver PIPAC along with systemic chemotherapy, it also poses significant risks for mesothelioma patients and others with peritoneal cancer. ?Implementing a PIPAC program in association with ...

 


New Maintenance Therapy for Ovarian Cancer Seeks FDA Approval - Curetoday.com



Curetoday.com
 
New Maintenance Therapy for Ovarian Cancer Seeks FDA Approval 
Curetoday.com
... (sNDA) to the FDA for their drug Rubraca (rucaparib) to be used as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based ...

 


Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or ... - Medgadget (blog)



Medgadget (blog)
 
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or ... 
Medgadget (blog)
... Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroreport_id Cancer, Acral Lentiginous Melanoma, ...

 


Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with ... - Dove Medical Press



Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with ... 
Dove Medical Press
Background: Goblet cell carcinomas (GCCs) of the appendix are rare and aggressive malignancies with early peritoneal dissemination. The aim of the present article is to describe our experience in the management of GCCs with peritoneal carcinomatosis ...

 


Speedy review for AZ' Lynparza in breast cancer - PharmaTimes - PharmaTimes



PharmaTimes
 
Speedy review for AZ' Lynparza in breast cancer - PharmaTimes 
PharmaTimes
AstraZeneca's and MSD's Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP ...

and more » 


FDA Approval Sought for Maintenance Rucaparib in Ovarian Cancer - OncLive



OncLive
 
FDA Approval Sought for Maintenance Rucaparib in Ovarian Cancer 
OncLive
A supplemental new drug application has been submitted to the FDA for rucaparib as maintenance treatment for patients with recurrent epithelial ovarian, ...
ARIEL3 ? broad benefit of PARP inhibitors in ovarian cancer Nature.com

all 2 news articles » 


Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients ... - Business Wire (press release)



Weekly Register
 
Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients ... 
Business Wire (press release)
ARIEL3 is a double-blind, placebo-controlled trial of rucaparib that enrolled 564 women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer. The primary efficacy analysis evaluated three prospectively defined ...
Clovis Oncology, Inc. - CLVS - Stock Price Today - Zacks Zacks Investment Research

all 100 news articles »